We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
DxGen Corp.

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
03 Mar 2021 - 05 Mar 2021
Virtual Venue
06 Mar 2021 - 10 Mar 2021
Virtual Venue

Angiopoietin-Like 2 Is a Biomarker for Diabetic Foot Patients

By LabMedica International staff writers
Posted on 14 Jan 2021
Print article
Image: Human Total Angiopoietin ELISA assay (Photo courtesy of Immuno-biological laboratories Co).
Image: Human Total Angiopoietin ELISA assay (Photo courtesy of Immuno-biological laboratories Co).
Diabetic foot ulcers (DFUs) are one of the common complications in type 2 diabetes mellitus
patients and are chartered by lower extremity vascular obstructions, persistent foot infections, ulcers, and deep tissue destruction.

Circulating angiopoietin-like 2 (ANGPTL2) protein levels are known to be significantly increased in numerous chronic inflammatory diseases and are associated with the diagnosis and/or prognosis of cardiovascular diseases, diabetes, chronic kidney disease, and various types of cancers.

Endocrinologists at Beijing Luhe Hospital (Beijing, China) recruited a total of 68 participants with type 2 diabetes mellitus (T2DM) including 28 patients with DFU and 40 diabetic patients without DFUs. The diagnosis of T2DM was based on the 1999 World Health Organization Criteria, which fulfills random blood glucose ≥11.1 mmol/L and/or fasting blood glucose (FBG) ≥ 7.0 mmol/L and/or 2 hour blood glucose, during an oral glucose tolerance test (OGTT) ≥ 11.1 mmol/L.

Routine laboratory measurements were performed, including fasting plasma glucose (FBG, mmol/L), alanine transaminase (ALT,U/L), aspartate transaminase (AST,U/L), glutamyl transpeptidase (γ-GT,U/L), triglyceride (TG, mmol/L), total cholesterol (CHO, mmol/L), low density lipoprotein cholesterol (LDL-C, mmol/L), high density lipoprotein cholesterol (HDL-C, mmol/L), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and white blood cell count (WBC). Serum ANGPTL2 was measured by using a commercially available human ELISA kits (Immuno-biological laboratories Co., Ltd., Fujioka-Shi, Japan) and Vascular endothelial growth factor (VEGF) (R&D Systems, Minneapolis, MN, USA).

The scientists reported that serum levels of ANGPTL2 were significantly higher in patients with DFUs than those in diabetic control ((T2DM versus DFU: 4.221 ± 1.301 versus 6.561 ± 2.335 μg/L). Serum ANGPTL2 levels were higher in the advanced stages of DFUs. Spearman correlation analysis revealed strong positive associations of ANGPTL2 with CRP, VEGF and ESR in all subjects. In addition, serum ANGPTL2 was still positively correlated with DFUs stage after adjusting the risk factors. After adjusting for age, sex, HbA1c and duration of diabetes, ANGPTL2 was found to be independently associated with the presence of DFUs.

The authors concluded that circulating ANGPTL2 levels are an independent risk factor for DFUs and are closely related to the severity of diabetic foot. ANGPTL2 may play important roles in the development of DFUs. The study was originally published on November 30, 2020 in the journal BMC Endocrine Disorders.

Related Links:
Beijing Luhe Hospital
Immuno-biological laboratories Co., Ltd
R&D Systems


New
Gold Supplier
COVID-19 Test
ID NOW COVID-19
Nucleic Acid Purification Kit
Maxwell RSC Viral Total Nucleic Acid Purification Kit
COVID-19 Anitibody Test
TGS COVID-19 IgG
SARS-CoV-2 RT-PCR Test
CareGene N-CoV RT-PCR Kit

Print article

Channels

Molecular Diagnostics

view channel
Image: Micrograph of a colorectal adenocarcinoma (Photo courtesy of Wikimedia Commons)

Plasma or Urine Liquid Biopsy Tests May Guide Colorectal Cancer Treatment

A recent paper suggested that liquid biopsy examination of blood or urine could aid in evaluating the effectiveness of therapy for colorectal cancers that had begun to metastasize beyond the site of the... Read more

Industry

view channel
Image: Sysmex CN-Series automated blood coagulation analyzer (Photo courtesy of Sysmex Corporation)

Siemens and Sysmex Extend Agreement to Provide One of the Largest Portfolios of Hemostasis Testing Systems and Reagents

Siemens Healthineers (Erlangen, Germany) and Sysmex Corporation (Kobe, Japan) have renewed their long-standing global supply, distributorship, sales and service agreement for a broad portfolio of hemostasis... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.